Juno Therapeutics Inc (JUNO) : Crestline Management Lp reduced its stake in Juno Therapeutics Inc by 33.14% during the most recent quarter end. The investment management company now holds a total of 17,348,799 shares of Juno Therapeutics Inc which is valued at $634.1 Million after selling 8,600,000 shares in Juno Therapeutics Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.Juno Therapeutics Inc makes up approximately 100.00% of Crestline Management Lp’s portfolio.
Other Hedge Funds, Including , Alliancebernstein boosted its stake in JUNO in the latest quarter, The investment management firm added 20 additional shares and now holds a total of 15,286 shares of Juno Therapeutics Inc which is valued at $558,703.Blackrock Group Ltd boosted its stake in JUNO in the latest quarter, The investment management firm added 4,609 additional shares and now holds a total of 34,653 shares of Juno Therapeutics Inc which is valued at $1.3 Million. Bluecrest Capital Management Ltd sold out all of its stake in JUNO during the most recent quarter. The investment firm sold 10,523 shares of JUNO which is valued $391,140.Rhumbline Advisers reduced its stake in JUNO by selling 250 shares or 2.28% in the most recent quarter. The Hedge Fund company now holds 10,704 shares of JUNO which is valued at $397,868.Public Employees Retirement Association Of Colorado boosted its stake in JUNO in the latest quarter, The investment management firm added 8,808 additional shares and now holds a total of 9,191 shares of Juno Therapeutics Inc which is valued at $386,849.
Juno Therapeutics Inc closed down -0.1 points or -0.25% at $40.28 with 9,62,081 shares getting traded on Wednesday. Post opening the session at $40.59, the shares hit an intraday low of $39.38 and an intraday high of $40.88 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Juno Therapeutics Inc reported $-0.78 EPS for the quarter, missing the analyst consensus estimate by $ -0.26 based on the information available during the earnings call on May 9, 2016. Analyst had a consensus of $-0.52. The company had revenue of $9.80 million for the quarter, compared to analysts expectations of $3.15 million. During the same quarter in the previous year, the company posted $-0.30 EPS.
Many Wall Street Analysts have commented on Juno Therapeutics Inc. Company shares were Reiterated by Maxim Group on Apr 11, 2016 to “Buy”, Firm has raised the Price Target to $ 80 from a previous price target of $78 .Citigroup Initiated Juno Therapeutics Inc on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $45.Juno Therapeutics Inc was Upgraded by Guggenheim to ” Buy” on Feb 17, 2016.
Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.